WALTHAM, Mass., Jan. 11, 2021 /PRNewswire/ -- Fresenius
Medical Care, the world's leading provider of products and services
for people with chronic kidney failure, announced today that
the company's Frenova division has enrolled the first participants
in its new initiative to develop the largest renal-focused genomic
registry in the world.
Along with this key milestone, the company also announced that
Ali Gharavi, MD, Chief of the
Division of Nephrology at Columbia
University Irving Medical Center and Professor of Medicine
at Columbia University Vagelos College
of Physicians and Surgeons, will lead the project and provide
scientific guidance as Principal Investigator.
As a contract clinical development services company dedicated
exclusively to medicines and medical products in renal research,
Frenova orchestrates studies within the clinical footprint of
Fresenius Medical Care, which provides dialysis treatments to about
350,000 patients around the globe. The renal-focused genomic
registry represents a new business line within Frenova, which is
based in Fresenius Medical Care's Global Medical Office.
As part of its growth strategy 2025, Fresenius Medical Care is
using digital technologies and the capability to analyze huge
amounts of data to develop new forms of renal therapy.
Nephrology has been under-represented in clinical research, even
as rapid progress in gene sequencing and analysis has led to
advances in precision medicine and individualized care in oncology,
cardiology and other medical areas. Frenova's new genomic registry
will contain genetic sequencing data from chronic kidney disease
patients worldwide, which will be used by researchers to improve
the understanding of kidney disease. Frenova developed the registry
after researchers identified the lack of a large-scale,
renal-focused registry of genomic and clinical data as a major
impediment to kidney disease research.
"The new Frenova registry will close this gap by generating data
that adds a clinical and genetic backbone to help support and fuel
scientific innovation," said Franklin W.
Maddux, MD, Global Chief Medical Officer of Fresenius
Medical Care. "The evidence for genetic drivers in kidney
diseases is substantial, but much larger data sets will be needed
to untangle the complex interactions that lead to kidney injury. By
combining clinical and genetic sequencing data from ethnically
and pathologically diverse participants, this genomic and
phenotypic research resource will help scientists better understand
how genetic variations in patients can lead to more precise
diagnoses and therapies that help improve outcomes by
individualizing care."
"Our renal-focused genomic registry will be a sustainable and
comprehensive tool for kidney-focused research," said Kurt Mussina, President of Frenova. "It will
bring patients, their families, patient advocacy groups, physicians
and researchers together in the common cause of improving the lives
of people living with kidney disease."
Learn more about Frenova Renal Research at
https://www.frenova.com/
Fresenius Medical Care is the world's leading provider of
products and services for individuals with renal diseases of which
around 3.5 million patients worldwide regularly undergo dialysis
treatment. Through its network of 4,073 dialysis clinics, Fresenius
Medical Care provides dialysis treatments for 349,167 patients
around the globe. Fresenius Medical Care is also the leading
provider of dialysis products such as dialysis machines or
dialyzers. Along with the core business, the company focuses on
expanding the range of related medical services in the field of
Care Coordination. Fresenius Medical Care is listed on the
Frankfurt Stock Exchange (FME) and on the New York Stock Exchange
(FMS).
For more information visit the Company's website at
www.freseniusmedicalcare.com.
Disclaimer
This release contains forward-looking statements that are subject
to various risks and uncertainties. Actual results could differ
materially from those described in these forward-looking statements
due to various factors, including, but not limited to, changes in
business, economic and competitive conditions, legal changes,
regulatory approvals, results of clinical studies, foreign exchange
rate fluctuations, uncertainties in litigation or investigative
proceedings, and the availability of financing. These and other
risks and uncertainties are detailed in Fresenius Medical Care AG
& Co. KGaA's reports filed with the U.S. Securities and
Exchange Commission. Fresenius Medical Care AG & Co. KGaA does
not undertake any responsibility to update the forward-looking
statements in this release.
Media Contacts
Michael
Gavin
T +49 6172 608-2978
michael.gavin@fresenius.com
Brad Puffer
T +1 781 699-3331
Brad.Puffer@fmc-na.com
Contact for analysts and investors
Dr. Dominik Heger
T +49 6172 609-2601
dominik.heger@fmc-ag.com
www.freseniusmedicalcare.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/fresenius-medical-cares-frenova-enrolls-patients-in-initiative-to-build-worlds-largest-genomic-registry-targeting-kidney-disease-301204788.html
SOURCE Fresenius Medical Care Holdings, Inc.